Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer cachexia

M J Tisdale1

  • 1Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.

Anti-Cancer Drugs
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Cancer cachexia, a wasting syndrome, involves significant weight loss and reduced survival. Targeting tumor-derived factors offers a novel therapeutic approach beyond nutritional support.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCg) Attenuates Skeletal Muscle Atrophy in a Rat Model of Sarcopenia.

The Journal of frailty & aging·2016
Same author

Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle.

British journal of cancer·2014
Same author

Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle.

Cellular signalling·2012
Same author

Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).

British journal of cancer·2011
Same author

Studies on the anti-obesity activity of zinc-α2-glycoprotein in the rat.

International journal of obesity (2005)·2010
Same author

Studies on the antiobesity effect of zinc-α2-glycoprotein in the ob/ob mouse.

International journal of obesity (2005)·2010

Area of Science:

  • Oncology
  • Metabolic Disorders
  • Cancer Research

Background:

  • Cachexia is prevalent in cancer patients, leading to weight loss, muscle depletion, and reduced survival.
  • It diminishes chemotherapy response and is not reversed by nutritional support alone, indicating underlying metabolic derangements.
  • Tumor-induced metabolic abnormalities, beyond anorexia, are key drivers of cancer cachexia.

Purpose of the Study:

  • To explore the mechanisms and mediators of cancer cachexia.
  • To identify potential therapeutic targets for reversing cachexia and improving patient outcomes.
  • To investigate the role of tumor-derived factors in host tissue catabolism and tumor growth.

Main Methods:

  • Review of postulated mediators of cancer cachexia, categorized into hormone-like factors and cytokines.

Related Experiment Videos

  • Analysis of agents that reverse cachexia, including those stimulating food intake and those inhibiting lipid mobilizing factor (LMF).
  • Evaluation of the impact of cachexia reversal agents on tumor growth.

    • Main Results:

    • Cancer cachexia involves direct catabolism by tumor-derived factors like LMF and indirect metabolic alterations via cytokines (e.g., TNF-α, IL-6).
    • Agents stimulating food intake can paradoxically promote tumor growth.
    • Agents directly inhibiting LMF show potential as tumor growth inhibitors, suggesting a link between host tissue catabolism and tumor progression.

    Conclusions:

    • Cancer cachexia is driven by complex tumor-induced metabolic changes, not just anorexia.
    • Targeting tumor-derived catabolic factors, like LMF, offers a promising therapeutic strategy for cachexia.
    • Inhibiting host tissue catabolism may represent a novel chemotherapeutic approach by impacting tumor growth.